Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies
Authors: Carlos Sanchez-Piedra, Cesar Diaz-Torne, Javier Manero, José M Pego-Reigosa, Íñigo Rúa-Figueroa, Miguel A Gonzalez-Gay, Juan Gomez-Reino, Jose M Alvaro-Gracia
Journal: Annals of the Rheumatic Diseases (2020)

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapiesFrom the beginning of the COVID-19 pandemic, more than 4.7 million cases have been detected in the world, Spain being one of the countries hardest hit by the SARS-CoV-2. 1 The role of the immune system and immunomodulatory therapies in the evolution of this infection is still controversial. 2 The study of patients with rheumatic and musculoskeletal diseases (RMDs) such as rheumatoid arthritis (RA), spondyloarthropathies (SpA) or systemic lupus erythematosus, treated with immunomodulatory therapies is essential to understand the prognosis of COVID-19 in this specific population and to the management of these patients.BIOBADASER is a multicentre prospective observational registry promoted by the Spanish Society of Rheumatology (SER) and supported by the Spanish Agency of Drugs and Medical Devices.It is aimed at assessing safety in patients with RMDs starting treatment with any biological (bDMARD) or targeted synthetic diseasemodifying antirheumatic drug (tsDMARD).More than 6600 patients are prospectively followed up in BIOBADASER 3.0.This report describes the clinical characteristics and outcomes of patients with COVID-19 in BIOBADASER.We have identified 41 patients with RMDs treated with bDMARD and tsDMARD diagnosed of COVID-19 at 15 hospitals in the registry.Thirty-one patients were diagnosed because positive PCR test for SARS-CoV-2, and 10 patients because a highly compatible clinical picture and close contact with confirmed positive cases.Table 1 shows baseline characteristics of the patients.Twenty-five (61.0%) patients were female and 16 (39,0%) male, with a mean age of 59.4 years.They had long-standing (12.8 years) refractory (three previous bDMARD/ tsDMARDs) diseases with 5.7 years of bDMARD/tsDMARD therapy duration.Twenty-one patients (51.2%) had RA.Comorbidities included hypertension (36.6%), past or current smoker (36.8%), diabetes (9.8%) and high body mass index (BMI) (27.7 (5.6) kg/m 2mean (SD)).Eighteen patients (43.9%) were using TNF inhibitors, seven JAK inhibitors (17.1%, 9.8% baricitinib and 7.3% tofacitinib) and five (12.2%)IL-6 inhibitors.Seventeen (41.5%) patients were using methotrexate and four (9,8%) hydroxychloroquine.Three patients died (7.3%); a 63-year-old RA male on anakinra-plus prednisone 5 mg/day-(comorbidities: smoker, BMI 34.6); a 56-year-old SpA female on secukinumab-no glucocorticoids-(past smoker, BMI 28.4) and a 91-year-old vasculitis female on rituximab-plus prednisone 5 mg/day-(hypertension).Hospitalisation was required in 28 patients (68.3%) and intensive care unit (ICU) admission in 6. Thirty-five (85.4%) patients are fully recovered at the moment of this analysis, and three patients are still hospitalised, none in ICU.Data on COVID-19 in patients with RMDs is still scarce. 3-6Because of the rapid evolution of the pandemic, it is important to accrue information on the clinical course of rheumatic patients on bDMARD/tsDMARDs developing COVID-19.The reduced number of patients in our study limits the possibility of drawing solid conclusions.However, these findings point in the direction that COVID-19 course and mortality in patients on July 22, 2023 by guest.